date,title,source
Oct-31-18,"Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018",GlobeNewswire
Nov-07-18,"Calithera (CALA) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-07-18,Calithera: 3Q Earnings Snapshot,Associated Press
Nov-08-18,Edited Transcript of CALA earnings conference call or presentation 7-Nov-18 10:00pm GMT,Thomson Reuters StreetEvents
Nov-09-18,"New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences  Factors of Influence, Major Initiatives and Sustained Production",GlobeNewswire
Nov-21-18,Intrinsic Calculation For Calithera Biosciences Inc (NASDAQ:CALA) Shows Investors Are Overpaying,Simply Wall St.
Nov-30-18,Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference,GlobeNewswire
Jan-07-19,Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Companys Pipeline,GlobeNewswire
Jan-18-19,"What Did Calithera Biosciences, Inc.s (NASDAQ:CALA) CEO Take Home Last Year?",Simply Wall St.
Jan-28-19,"Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences  Research Highlights Growth, Revenue, and Consolidated Results",GlobeNewswire
Feb-04-19,Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma,GlobeNewswire
Feb-21-19,Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis,GlobeNewswire
Feb-22-19,Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference,GlobeNewswire
